Follow us on Twitter
twitter icon@FreshPatents


C Syndrome patents

      

This page is updated frequently with new C Syndrome-related patent applications.




 Novel biological detection  dioxins in serum, and a diagnostic use therefor in metabolic syndrome and related conditions patent thumbnailNovel biological detection dioxins in serum, and a diagnostic use therefor in metabolic syndrome and related conditions
The present invention relates to a novel biological detection method for dioxins in serum and a diagnostic use thereof in metabolic syndrome and related conditions. More particularly, according to the present invention, a significant correlation between dioxin content in serum and physical variables has been confirmed by measuring luciferase activity through the use of serum as a whole and cells transformed with a recombinant vector comprising a gene construct in which a dioxin responsive element, a promoter and a reporter gene are operably linked.
University-industry Cooperation Group Of Kyung Hee


 Phenyl-substituted nicotinic ligands, and methods of use thereof patent thumbnailPhenyl-substituted nicotinic ligands, and methods of use thereof
Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, lewy body dementia, attention deficit hyperactivity disorder (adhd), parkinson's disease, huntington's disease, tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.. .
Duke University


 Composition for preventing and treating non-alcoholic fatty liver diseases patent thumbnailComposition for preventing and treating non-alcoholic fatty liver diseases
A composition includes a black chokeberry extract and at least one of a thistle extract, a black hoof mushroom extract and a mixture thereof. The composition is effective in preventing and treating non-alcoholic fatty liver disease caused by accumulation of fat in the liver due to excessive intake of nutrients or metabolic syndrome regardless of alcohol intake.
Jbk Natural Medicine Institute


 Activation of amp-protein activated kinase by oxaloacetate compounds patent thumbnailActivation of amp-protein activated kinase by oxaloacetate compounds
The present invention relates to oxaloacetate compounds that activate amp-activated protein kinase (ampk), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, alzheimer's disease, and cancer.. .

 Chimeric fibroblast growth factor 19 proteins and methods of use patent thumbnailChimeric fibroblast growth factor 19 proteins and methods of use
The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf 19 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University


 Sweetness receptor antagonist patent thumbnailSweetness receptor antagonist
Wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.. .

 Systems and methods of improving metabolic syndrome patent thumbnailSystems and methods of improving metabolic syndrome
Methods for improving metabolic syndrome in a subject are provided. Methods include positioning a therapy delivery device on a neural target site that contributes to immune activity of the subject.
Ohio State Innovation Foundation


 Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes patent thumbnailMethods and pharmaceutical compositions for the treatment of myelodysplastic syndromes
The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of gata-1 by preventing sequestration of hsp70 in the cytoplasm.
Inserm (institut National De La SantÉ Et Da La Recherche MÉdicale)


 Peptide analogs for treating diseases and disorders patent thumbnailPeptide analogs for treating diseases and disorders
Provided herein are peptides, that in combination with metformin, are effective for the treatment of type i diabetes, type ii diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences seq id no: 11, seq id no: 12, seq id no: 13, seq id no: 14, seq id no: 15, seq id no: 16, seq id no: 17, seq id no: 19, seq id no: 20, seq id no: 21, seq id no: 22, seq id no: 23, and seq id no: 24..
Keybioscience Ag


 Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders patent thumbnailChimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders
The present invention relates to chimeric proteins that include an n-terminus coupled to a c-terminus, where the n-terminus includes an n-terminal portion of fibroblast growth factor 21 (“fgf21”) and the c-terminus includes a c-terminal portion of fibroblast growth factor 19 (“fgf19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased fgf21-βklotho-fgf receptor complex formation, methods of causing increased fgf21 receptor agonist-βklotho-fgf receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βklotho-fgf receptor complex involving the use of chimeric proteins of the present invention..
New York University


T cell receptor-like antibodies specific for a wti peptide presented by hla-a2

The present invention provides antigen binding proteins that specifically bind to wilms' tumor protein (wt1), including humanized, chimeric and fully human antibodies against wt1, antibody fragments, chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to hla-a0201-restricted wt1 peptide.
Eureka Therapeutics, Inc.

Cd33 binding agents

The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to cd33 binding agents for use in such therapies, e.g.
Boehringer Ingelheim International Gmbh

Combination therapy for mds

Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (mds) and acute myeloid leukemia (aml). The disclosed methods include administering to an individual in need of such treatment a composition that may include an irak1/4 inhibitor.
Children's Hospital Medical Center

Novel compounds as diacylglycerol acyltransferase inhibitors

This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc

Therapy for complications of diabetes

A method for enhancing glycemic control and/or insulin sensitivity to a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin a (eta) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective eta receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective eta receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension.
Abbvie Deutschland Gmbh & Co. Kg

Compositions and methods for the treatment of diabetes and pre-diabetes

The invention relates to the compounds and compositions of formula i, formula ii, formula iii, formula iv, formula v, formula vi or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of dipeptidyl peptidase-4 inhibitor and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient

Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.. .
Industry Foundation Of Chonnam National University

Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome

The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain dpp-4 inhibitor, as well as to the use of a certain dpp-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.. .
Boehringer Ingelheim International Gmbh

Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gbs), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals, Inc.

Polypeptides and antibodies for assessing predisposition for myelodysplastic syndromes or myelogenous tumor, and screening therapeutic drugs therefor

The present invention provides polypeptide and antibody for assessing predisposition of myelodysplastic syndrome or myeloid tumor, and method for screening therapeutic drugs therefor. The polypeptide comprises at least a portion of the u2af35 gene, at least a portion of the zrsr2 gene, at least a portion of the sfrs2 gene, or at least a portion of the sf3b1 gene, and is able to serve as a marker for evaluating predisposition for myelodysplastic syndromes or a myelogenous tumor..
The University Of Tokyo

Compositions and methods for treating diabetes

The present disclosure is a compound, a method of making the compound and method of using such compound preferably in the form of a dietary supplement that, when administered, is capable of treating prediabetes, diabetes, insulin resistance or metabolic syndrome. The unique combination of the composition is preferably administered orally.

Composition comprising 7-hydroxymatairesinol

A composition comprising 7-hydroxymatairesinol (hmr), or a stereoisomer, salt, complex, adduct or derivative thereof, or an extract containing them for preventing, alleviating or ameliorating the metabolic syndrome conditions.. .
Linnea S.a.

Hepatocyte growth factor mimics as therapeutic agents

Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, neurodegenerative disease, diabetes and metabolic syndrome, cancer, and defective wound healing..
Washington State University

Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds

A method of treating acute myeloid leukemia, acute lymphoblastic leukemia, high risk myelodysplastic syndrome, and/or hr-mds/aml in a mammal by administering a solid dispersion comprising an amorphous thienotriazolodiazepine compound of the formula (1) wherein r1 is alkyl having a carbon number of 1-4, r2 is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, r3 is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —nr5-(ch2)m r6 wherein r5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and r6 is phenyl or pyridyl optionally substituted by a halogen atom.. .
Oncoethix Gmbh

Compositions and methods for treating fatty tissue buildup

The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
The Metrohealth System



C Syndrome topics:
  • C Syndrome
  • Metabolic Syndrome
  • Insulin Resistance
  • Metabolism
  • Dyslipidemia
  • Inflammation
  • Syndrome X
  • Liver Disease
  • Fatty Liver
  • Nephropathy
  • Type 2 Diabetes
  • Retinopathy
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Hypertension


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to C Syndrome for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for C Syndrome with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2261

    file did exist - file did put2601

    3 - 1 - 51